Exelixis
EXEL
#1579
Rank
โ‚ฌ10.29 B
Marketcap
36,78ย โ‚ฌ
Share price
-0.36%
Change (1 day)
76.85%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) Fails to deliver data

Key failure to deliver metrics for Exelixis:

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Exelixis (EXEL) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for Exelixis (EXEL) - since 2013

Volume in USD (price x number of shares), data since 2013

Exelixis (EXEL) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2025โ‚ฌ1.76 M-85.42%
2024โ‚ฌ12.08 M86.29%
2023โ‚ฌ6.48 M-41.81%
2022โ‚ฌ11.14 M-31.9%
2021โ‚ฌ16.36 M-20.71%
2020โ‚ฌ20.64 M303.63%
2019โ‚ฌ5.11 M-70.5%
2018โ‚ฌ17.33 M8.82%
2017โ‚ฌ15.92 M-17.35%
2016โ‚ฌ19.27 M-75.68%
2015โ‚ฌ79.23 M19.37%
2014โ‚ฌ66.37 M258.49%
2013โ‚ฌ18.51 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3 months) FTD volume (1 year) Country
โ‚ฌ81.01 Mโ‚ฌ0.17 B๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚ฌ1.21 Mโ‚ฌ47.51 M๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ80.49 Mโ‚ฌ0.13 B๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.16 Bโ‚ฌ0.47 B๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ37.38 Mโ‚ฌ0.21 B๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ15.09 Mโ‚ฌ0.22 B๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ24.22 Mโ‚ฌ0.33 B๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.04 Mโ‚ฌ0.84 M๐Ÿ‡บ๐Ÿ‡ธ USA
N/Aโ‚ฌ0.04 M๐Ÿ‡บ๐Ÿ‡ธ USA